VEGFA and endometrial cancer: For endorsement of re-profiling of our findings to endometrial cancer, a VEGFA inhibitor, bevacizumab, was shown to be well tolerated and active in recurrent or persistent endometrial cancer based on progression-free survival at 6 months [14].